Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230001/S010

ColoSense

Geneoscopy, Inc. · Decision date Aug 14, 2025

FDA DECISIONP230001/S010

What did the FDA decide?

FDA records P230001/S010 as a supplement to PMA P230001, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 14, 2025.

FDA approval order statement

approval to modify the volume of specific kit reagents during the manufacturing process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Aug 14, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230001/S010
Regulatory pathway
PMA supplement
Product code
SBB
Decision code
OK30
Decision date
Aug 14, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.

Product code
SBB
FDA device class
3

For the original device and its historical approval scope, see PMA P230001. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230001/S010 received

    Application receipt date recorded by FDA.

  2. P230001/S010 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230001

Product / regulatory recordCompanyPathwayDecision dateSource
ColoSenseP230001
Geneoscopy, Inc.PMA approvalMay 3, 2024FDA
ColoSenseP230001/S009
Geneoscopy, Inc.PMA supplementSep 15, 2025FDA
ColoSenseP230001/S011
Geneoscopy, Inc.PMA supplementOct 24, 2025FDA
ColoSenseP230001/S012
Geneoscopy, Inc.PMA supplementAug 27, 2026FDA
ColoSenseP230001/S014
Geneoscopy, Inc.PMA supplementSep 8, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Geneoscopy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2220 Welsch Industrial Ct., St. Louis, MO, 63146

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records